Clinical Scorecard: Associations of Lipoprotein (a) and Apolipoprotein B Levels with Clinical Characteristics in Patients Experiencing Dyslipidemia and Cardiovascular Disease
At a Glance
Category
Detail
Condition
Dyslipidemia and Cardiovascular Disease
Key Mechanisms
Lipoprotein(a) and Apolipoprotein B as independent biomarkers of cardiovascular risk reflecting atherogenic particle burden.
Target Population
Adults with dyslipidemia and established cardiovascular disease.
Care Setting
Tertiary medical center for cardiometabolic risk profiling.
Key Highlights
Mean Lp(a) concentration was 30.14 ± 31.50 mg/dL.
ApoB averaged 119.87 ± 36.01 mg/dL.
ApoB significantly correlates with total cholesterol, triglycerides, and LDL-C.
GGT, creatinine, and uric acid influence Lp(a) variability.
Elevated Lp(a) and ApoB levels are associated with increased cardiovascular risk.
Guideline-Based Recommendations
Diagnosis
Assess Lp(a) and ApoB levels in patients with dyslipidemia and cardiovascular disease.
Management
Consider novel therapeutic strategies for elevated Lp(a) including PCSK9 inhibitors and antisense oligonucleotides.
Monitoring & Follow-up
Regularly monitor Lp(a) and ApoB levels to evaluate cardiovascular risk.
Risks
Elevated Lp(a) and ApoB levels are linked to residual cardiovascular risk despite lipid-lowering therapy.
Patient & Prescribing Data
Adults aged 19 to 90 years with measurable Lp(a) and ApoB values.
Therapies such as statins and PCSK9 inhibitors can significantly reduce ApoB levels.
Clinical Best Practices
Integrate Lp(a) and ApoB assessment into routine cardiovascular risk profiling.
Evaluate hepatic and renal function markers when assessing Lp(a) levels.
by Luana Alexandrescu, Daria Maria Alexandrescu, Ionut Tiberiu Tofolean, Doina Ecaterina Tofolean, Steliana Pindichi, Eugen Dumitru, Bogdan Campineanu, Cristina Aftenie, Andreea Nelson Twakor, Alexandra Herlo, Elena Rusu, Diana Raluca Baicu, Madalina Ilie, Filip-Vasile Berariu, Laura Maria Condur
Creatine's ATP-buffering trick isn't just for biceps. In mice, it juices up dendritic cells' energy supply, sharpening T-cell priming and shrinking tumors on daily injections. Human DCs got the memo too, at least in a dish. Early days, but a fun plot twist for gym-bag chemistry.
